This is the first clinical decision rule to distinguish the risk of severe infection at different times, according to the type of cancer.
Results show survival that is three times longer for a combination of ivosidenib plus azacitidine versus azacitidine alone in a distinct...
With nearly 40% of AML patients unable to take part in their own final code discussions, families struggle to guess what their loved ones would...
Rare Diseases Report 2021
Precision medicine makes groundbreaking strides in treating myeloid malignancies by integrating individual molecular data into patient care.
Among 46 patients, nearly all seroconverted after second shot.
COVID-19 death risks for acute leukemias were driven by poor physician-assessed prognoses and opting out of recommended ICU care.